Community Research and Development Information Service - CORDIS

Results 1 - 10 of 180
Results/page:
12 3 4 5 6 7 8 9 10 > >| 
Next-generation biopharmaceutical downstream process
ID: 635557
Start date: 2015-03-01, End date: 2019-02-28
The scope of the project is the optimization of downstream process (DSP) for the production of Biopharmaceuticals. Biopharmaceuticals have been successfully used as efficient therapeutic drugs for many pathophysiological conditions since the first recombinant product, insulin...
Programme: H2020-EU.2.1.4.
Record Number: 193337
Last updated on: 2017-05-17
Periodic Reporting for period 1 - nextBioPharmDSP (Next-generation biopharmaceutical downstream process)
The scope of the project is the optimization of downstream processing (DSP) for the production of Biopharmaceuticals. Biopharmaceuticals have been successfully used as efficient therapeutic drugs for many pathophysiological conditions since the first recombinant product...
Programme: H2020-EU.2.1.4.
Record Number: 193053
Last updated on: 2016-12-16
Novel Immunotherapeutic Vaccine for the treatment of Alzheimer’s disease
ID: 773570
Start date: 2017-03-01, End date: 2017-08-31
The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain. AD is a therapeutic area...
Programme: H2020-EU.2.1.4.
Record Number: 210651
Last updated on: 2017-05-17
A big jump in preventing problems in refractive surgery for myopia
ID: 775591
Start date: 2017-06-01, End date: 2017-08-31
The treatment of myopia using the excimer laser technology has been standardized globally. It is the main business for ophthalmologists in private practice. Most of patients undergoing laser refractive surgery achieve a good outcome, but there is a reduced volume of patients...
Programme: H2020-EU.2.1.4.
Record Number: 210702
Last updated on: 2017-05-17
Rational Design and Construction of Viral Based Products
ID: 775169
Start date: 2017-06-01, End date: 2017-09-30
In order to be fully effective as an oncolytic virus or vaccine, achieving of precise and specific traits are pivotal. However, current technologies are limited to the confines of a virus’s existing biological make-up. They are left with manipulation of genes within the...
Programme: H2020-EU.2.1.4.
Record Number: 210691
Last updated on: 2017-05-18
Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry
ID: 773750
Start date: 2017-06-01, End date: 2017-09-30
Genome Biologics’ novel drug discovery platform addresses the inefficiencies in pre-clinical studies with a unique combination of genomics, molecular science and big data analytics. Using patented single cell transgenic technology, the platform can express 50 different genes...
Programme: H2020-EU.2.1.4.
Record Number: 210657
Last updated on: 2017-05-17
Feasibility study for registration of medicine RIGVIR with the European Medicine Agency
ID: 736051
Start date: 2016-08-01, End date: 2017-01-31
Cancer is one of the most dangerous life-threatening disorders for humanity of which melanoma is considered to be one ofthe most dangerous and aggressive. There are a number of therapies available to treat melanoma. However, thesetreatments are generally marginally effective...
Programme: H2020-EU.2.1.4.
Record Number: 205120
Last updated on: 2017-02-27
Periodic Reporting for period 1 - RIGVIR (Feasibility study for registration of medicine RIGVIR with the European Medicine Agency)
The Project and accomplished Feasibility study was aimed to ascertain framework for the registration process for medicine RIGVIR® in European Medicine Agency (further in text EMA) and development of Briefing document that fulfils EMA requirements. The special approach was...
Programme: H2020-EU.2.1.4.
Record Number: 198670
Last updated on: 2017-05-23
Start date: 2017-06-21, End date: 2017-06-23
The EU-funded EuroNano Forum (ENF2017), organised by the upcoming Maltese Presidency of the Council of the European Union, will take place in Valletta, Malta, from 21 to 23 June 2017.
Programme: H2020-EU.2.1.5.
Record Number: 144070
Last updated on: 2016-11-07
Available languages: DE, EN, ES, FR, IT, PL
Exploiting native endowments by re-factoring, re-programming and implementing novel control loops in Pseudomonas putida for bespoke biocatalysis
ID: 635536
Start date: 2015-05-01, End date: 2019-04-30
We aim to engineer the lifestyle of Pseudomonas putida to generate a tailored, re-factored chassis with highly attractive new-to-nature properties, thereby opening the door to the production of thus far non-accessible compounds. This industrially driven project capitalises on...
Programme: H2020-EU.2.1.4.
Record Number: 193335
Last updated on: 2016-11-29
12 3 4 5 6 7 8 9 10 > >| 
List retrieved on: 2017-05-24
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top